Entos Pharmaceuticals已获进行COVID-19 DNA疫苗I期临床试验的资金支持

2020-10-24 Allan MedSci原创

生物技术公司Entos Pharmaceuticals近日宣布,该公司已从加拿大国家研究理事会工业研究援助计划 (NRC IRAP)中获得了高达500万加元的资金。

生物技术公司Entos Pharmaceuticals近日宣布,该公司已从加拿大国家研究理事会工业研究援助计划 (NRC IRAP)中获得了高达500万加元的资金。

Entos开发了一种名为Covigenix的Fusogenix DNA疫苗,该疫苗在临床前研究中诱导了强烈的中和抗体反应以及针对SARS-CoV-2(引起COVID-19的病毒)的T细胞反应。NRC IRAP的支持将有助于Entos的COVID-19 DNA疫苗研究进入I期临床试验。

Entos Pharmaceuticals首席执行官John Lewis表示:“Entos很荣幸能成为获得NRC IRAP支持的加拿大创新公司之一。我们很高兴能利用这笔资金推进Covigenix的I期人体临床试验”。

Entos迫切需要为加拿大人以及全球人口开发和生产针对COVID-19的安全有效的疫苗,以确保持久的保护。Entos正在积极寻求政府和投资者的资金支持,以推进II期和III期人体临床试验,并加速Covigenix GMP生产能力的提升。

 

原始出处:

https://www.firstwordpharma.com/node/1767895?tsid=4

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (11)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2088832, encodeId=b5462088832e8, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10189, encryptionId=53961018913, topicName=I期临床试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45b2276, createdName=839640778, createdTime=Tue Feb 23 16:10:34 CST 2021, time=2021-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1653110, encodeId=c2ec1653110d1, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10187, encryptionId=5b011018e07, topicName=I期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc1f24335670, createdName=医生2402, createdTime=Wed Jun 09 03:10:34 CST 2021, time=2021-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1656034, encodeId=fdb81656034b7, content=<a href='/topic/show?id=2a011829d7' target=_blank style='color:#2F92EE;'>#ACE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1829, encryptionId=2a011829d7, topicName=ACE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=635024767990, createdName=shanyongle, createdTime=Thu Oct 07 16:10:34 CST 2021, time=2021-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908609, encodeId=2c4a190860901, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Sat Nov 14 22:10:34 CST 2020, time=2020-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1996377, encodeId=afd619963e74f, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Thu Aug 26 00:10:34 CST 2021, time=2021-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787689, encodeId=dfff1e87689cf, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Mon Jun 21 11:10:34 CST 2021, time=2021-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1423406, encodeId=0147142340606, content=<a href='/topic/show?id=075e6130ad' target=_blank style='color:#2F92EE;'>#DNA疫苗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6130, encryptionId=075e6130ad, topicName=DNA疫苗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e4853780813, createdName=mnda, createdTime=Mon Oct 26 01:10:34 CST 2020, time=2020-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1575213, encodeId=dafa15e5213bf, content=<a href='/topic/show?id=6b10112139c' target=_blank style='color:#2F92EE;'>#MACE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11213, encryptionId=6b10112139c, topicName=MACE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2c1f16064818, createdName=lfyang, createdTime=Mon Oct 26 01:10:34 CST 2020, time=2020-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=894209, encodeId=1429894209b8, content=新手新手 需要积分, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=81e45428646, createdName=ms9000001870934422, createdTime=Sat Oct 24 22:52:29 CST 2020, time=2020-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=894169, encodeId=26bd89416932, content=获益非浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIpJVcpECMUATt5iaMc09c4WsFcnLwnayPsFkPE92Gibj9T6rMfhSvaZhnjV8SeXr6Bcl4ddfC4m9Cg/132, createdBy=7d5c2384333, createdName=kulou0314, createdTime=Sat Oct 24 18:48:40 CST 2020, time=2020-10-24, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2088832, encodeId=b5462088832e8, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10189, encryptionId=53961018913, topicName=I期临床试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45b2276, createdName=839640778, createdTime=Tue Feb 23 16:10:34 CST 2021, time=2021-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1653110, encodeId=c2ec1653110d1, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10187, encryptionId=5b011018e07, topicName=I期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc1f24335670, createdName=医生2402, createdTime=Wed Jun 09 03:10:34 CST 2021, time=2021-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1656034, encodeId=fdb81656034b7, content=<a href='/topic/show?id=2a011829d7' target=_blank style='color:#2F92EE;'>#ACE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1829, encryptionId=2a011829d7, topicName=ACE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=635024767990, createdName=shanyongle, createdTime=Thu Oct 07 16:10:34 CST 2021, time=2021-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908609, encodeId=2c4a190860901, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Sat Nov 14 22:10:34 CST 2020, time=2020-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1996377, encodeId=afd619963e74f, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Thu Aug 26 00:10:34 CST 2021, time=2021-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787689, encodeId=dfff1e87689cf, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Mon Jun 21 11:10:34 CST 2021, time=2021-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1423406, encodeId=0147142340606, content=<a href='/topic/show?id=075e6130ad' target=_blank style='color:#2F92EE;'>#DNA疫苗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6130, encryptionId=075e6130ad, topicName=DNA疫苗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e4853780813, createdName=mnda, createdTime=Mon Oct 26 01:10:34 CST 2020, time=2020-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1575213, encodeId=dafa15e5213bf, content=<a href='/topic/show?id=6b10112139c' target=_blank style='color:#2F92EE;'>#MACE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11213, encryptionId=6b10112139c, topicName=MACE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2c1f16064818, createdName=lfyang, createdTime=Mon Oct 26 01:10:34 CST 2020, time=2020-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=894209, encodeId=1429894209b8, content=新手新手 需要积分, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=81e45428646, createdName=ms9000001870934422, createdTime=Sat Oct 24 22:52:29 CST 2020, time=2020-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=894169, encodeId=26bd89416932, content=获益非浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIpJVcpECMUATt5iaMc09c4WsFcnLwnayPsFkPE92Gibj9T6rMfhSvaZhnjV8SeXr6Bcl4ddfC4m9Cg/132, createdBy=7d5c2384333, createdName=kulou0314, createdTime=Sat Oct 24 18:48:40 CST 2020, time=2020-10-24, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2088832, encodeId=b5462088832e8, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10189, encryptionId=53961018913, topicName=I期临床试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45b2276, createdName=839640778, createdTime=Tue Feb 23 16:10:34 CST 2021, time=2021-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1653110, encodeId=c2ec1653110d1, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10187, encryptionId=5b011018e07, topicName=I期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc1f24335670, createdName=医生2402, createdTime=Wed Jun 09 03:10:34 CST 2021, time=2021-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1656034, encodeId=fdb81656034b7, content=<a href='/topic/show?id=2a011829d7' target=_blank style='color:#2F92EE;'>#ACE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1829, encryptionId=2a011829d7, topicName=ACE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=635024767990, createdName=shanyongle, createdTime=Thu Oct 07 16:10:34 CST 2021, time=2021-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908609, encodeId=2c4a190860901, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Sat Nov 14 22:10:34 CST 2020, time=2020-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1996377, encodeId=afd619963e74f, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Thu Aug 26 00:10:34 CST 2021, time=2021-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787689, encodeId=dfff1e87689cf, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Mon Jun 21 11:10:34 CST 2021, time=2021-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1423406, encodeId=0147142340606, content=<a href='/topic/show?id=075e6130ad' target=_blank style='color:#2F92EE;'>#DNA疫苗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6130, encryptionId=075e6130ad, topicName=DNA疫苗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e4853780813, createdName=mnda, createdTime=Mon Oct 26 01:10:34 CST 2020, time=2020-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1575213, encodeId=dafa15e5213bf, content=<a href='/topic/show?id=6b10112139c' target=_blank style='color:#2F92EE;'>#MACE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11213, encryptionId=6b10112139c, topicName=MACE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2c1f16064818, createdName=lfyang, createdTime=Mon Oct 26 01:10:34 CST 2020, time=2020-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=894209, encodeId=1429894209b8, content=新手新手 需要积分, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=81e45428646, createdName=ms9000001870934422, createdTime=Sat Oct 24 22:52:29 CST 2020, time=2020-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=894169, encodeId=26bd89416932, content=获益非浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIpJVcpECMUATt5iaMc09c4WsFcnLwnayPsFkPE92Gibj9T6rMfhSvaZhnjV8SeXr6Bcl4ddfC4m9Cg/132, createdBy=7d5c2384333, createdName=kulou0314, createdTime=Sat Oct 24 18:48:40 CST 2020, time=2020-10-24, status=1, ipAttribution=)]
    2021-10-07 shanyongle
  4. [GetPortalCommentsPageByObjectIdResponse(id=2088832, encodeId=b5462088832e8, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10189, encryptionId=53961018913, topicName=I期临床试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45b2276, createdName=839640778, createdTime=Tue Feb 23 16:10:34 CST 2021, time=2021-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1653110, encodeId=c2ec1653110d1, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10187, encryptionId=5b011018e07, topicName=I期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc1f24335670, createdName=医生2402, createdTime=Wed Jun 09 03:10:34 CST 2021, time=2021-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1656034, encodeId=fdb81656034b7, content=<a href='/topic/show?id=2a011829d7' target=_blank style='color:#2F92EE;'>#ACE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1829, encryptionId=2a011829d7, topicName=ACE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=635024767990, createdName=shanyongle, createdTime=Thu Oct 07 16:10:34 CST 2021, time=2021-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908609, encodeId=2c4a190860901, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Sat Nov 14 22:10:34 CST 2020, time=2020-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1996377, encodeId=afd619963e74f, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Thu Aug 26 00:10:34 CST 2021, time=2021-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787689, encodeId=dfff1e87689cf, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Mon Jun 21 11:10:34 CST 2021, time=2021-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1423406, encodeId=0147142340606, content=<a href='/topic/show?id=075e6130ad' target=_blank style='color:#2F92EE;'>#DNA疫苗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6130, encryptionId=075e6130ad, topicName=DNA疫苗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e4853780813, createdName=mnda, createdTime=Mon Oct 26 01:10:34 CST 2020, time=2020-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1575213, encodeId=dafa15e5213bf, content=<a href='/topic/show?id=6b10112139c' target=_blank style='color:#2F92EE;'>#MACE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11213, encryptionId=6b10112139c, topicName=MACE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2c1f16064818, createdName=lfyang, createdTime=Mon Oct 26 01:10:34 CST 2020, time=2020-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=894209, encodeId=1429894209b8, content=新手新手 需要积分, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=81e45428646, createdName=ms9000001870934422, createdTime=Sat Oct 24 22:52:29 CST 2020, time=2020-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=894169, encodeId=26bd89416932, content=获益非浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIpJVcpECMUATt5iaMc09c4WsFcnLwnayPsFkPE92Gibj9T6rMfhSvaZhnjV8SeXr6Bcl4ddfC4m9Cg/132, createdBy=7d5c2384333, createdName=kulou0314, createdTime=Sat Oct 24 18:48:40 CST 2020, time=2020-10-24, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=2088832, encodeId=b5462088832e8, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10189, encryptionId=53961018913, topicName=I期临床试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45b2276, createdName=839640778, createdTime=Tue Feb 23 16:10:34 CST 2021, time=2021-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1653110, encodeId=c2ec1653110d1, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10187, encryptionId=5b011018e07, topicName=I期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc1f24335670, createdName=医生2402, createdTime=Wed Jun 09 03:10:34 CST 2021, time=2021-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1656034, encodeId=fdb81656034b7, content=<a href='/topic/show?id=2a011829d7' target=_blank style='color:#2F92EE;'>#ACE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1829, encryptionId=2a011829d7, topicName=ACE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=635024767990, createdName=shanyongle, createdTime=Thu Oct 07 16:10:34 CST 2021, time=2021-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908609, encodeId=2c4a190860901, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Sat Nov 14 22:10:34 CST 2020, time=2020-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1996377, encodeId=afd619963e74f, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Thu Aug 26 00:10:34 CST 2021, time=2021-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787689, encodeId=dfff1e87689cf, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Mon Jun 21 11:10:34 CST 2021, time=2021-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1423406, encodeId=0147142340606, content=<a href='/topic/show?id=075e6130ad' target=_blank style='color:#2F92EE;'>#DNA疫苗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6130, encryptionId=075e6130ad, topicName=DNA疫苗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e4853780813, createdName=mnda, createdTime=Mon Oct 26 01:10:34 CST 2020, time=2020-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1575213, encodeId=dafa15e5213bf, content=<a href='/topic/show?id=6b10112139c' target=_blank style='color:#2F92EE;'>#MACE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11213, encryptionId=6b10112139c, topicName=MACE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2c1f16064818, createdName=lfyang, createdTime=Mon Oct 26 01:10:34 CST 2020, time=2020-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=894209, encodeId=1429894209b8, content=新手新手 需要积分, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=81e45428646, createdName=ms9000001870934422, createdTime=Sat Oct 24 22:52:29 CST 2020, time=2020-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=894169, encodeId=26bd89416932, content=获益非浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIpJVcpECMUATt5iaMc09c4WsFcnLwnayPsFkPE92Gibj9T6rMfhSvaZhnjV8SeXr6Bcl4ddfC4m9Cg/132, createdBy=7d5c2384333, createdName=kulou0314, createdTime=Sat Oct 24 18:48:40 CST 2020, time=2020-10-24, status=1, ipAttribution=)]
    2021-08-26 yb6560
  6. [GetPortalCommentsPageByObjectIdResponse(id=2088832, encodeId=b5462088832e8, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10189, encryptionId=53961018913, topicName=I期临床试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45b2276, createdName=839640778, createdTime=Tue Feb 23 16:10:34 CST 2021, time=2021-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1653110, encodeId=c2ec1653110d1, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10187, encryptionId=5b011018e07, topicName=I期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc1f24335670, createdName=医生2402, createdTime=Wed Jun 09 03:10:34 CST 2021, time=2021-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1656034, encodeId=fdb81656034b7, content=<a href='/topic/show?id=2a011829d7' target=_blank style='color:#2F92EE;'>#ACE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1829, encryptionId=2a011829d7, topicName=ACE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=635024767990, createdName=shanyongle, createdTime=Thu Oct 07 16:10:34 CST 2021, time=2021-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908609, encodeId=2c4a190860901, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Sat Nov 14 22:10:34 CST 2020, time=2020-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1996377, encodeId=afd619963e74f, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Thu Aug 26 00:10:34 CST 2021, time=2021-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787689, encodeId=dfff1e87689cf, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Mon Jun 21 11:10:34 CST 2021, time=2021-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1423406, encodeId=0147142340606, content=<a href='/topic/show?id=075e6130ad' target=_blank style='color:#2F92EE;'>#DNA疫苗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6130, encryptionId=075e6130ad, topicName=DNA疫苗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e4853780813, createdName=mnda, createdTime=Mon Oct 26 01:10:34 CST 2020, time=2020-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1575213, encodeId=dafa15e5213bf, content=<a href='/topic/show?id=6b10112139c' target=_blank style='color:#2F92EE;'>#MACE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11213, encryptionId=6b10112139c, topicName=MACE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2c1f16064818, createdName=lfyang, createdTime=Mon Oct 26 01:10:34 CST 2020, time=2020-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=894209, encodeId=1429894209b8, content=新手新手 需要积分, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=81e45428646, createdName=ms9000001870934422, createdTime=Sat Oct 24 22:52:29 CST 2020, time=2020-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=894169, encodeId=26bd89416932, content=获益非浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIpJVcpECMUATt5iaMc09c4WsFcnLwnayPsFkPE92Gibj9T6rMfhSvaZhnjV8SeXr6Bcl4ddfC4m9Cg/132, createdBy=7d5c2384333, createdName=kulou0314, createdTime=Sat Oct 24 18:48:40 CST 2020, time=2020-10-24, status=1, ipAttribution=)]
    2021-06-21 jj000001
  7. [GetPortalCommentsPageByObjectIdResponse(id=2088832, encodeId=b5462088832e8, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10189, encryptionId=53961018913, topicName=I期临床试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45b2276, createdName=839640778, createdTime=Tue Feb 23 16:10:34 CST 2021, time=2021-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1653110, encodeId=c2ec1653110d1, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10187, encryptionId=5b011018e07, topicName=I期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc1f24335670, createdName=医生2402, createdTime=Wed Jun 09 03:10:34 CST 2021, time=2021-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1656034, encodeId=fdb81656034b7, content=<a href='/topic/show?id=2a011829d7' target=_blank style='color:#2F92EE;'>#ACE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1829, encryptionId=2a011829d7, topicName=ACE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=635024767990, createdName=shanyongle, createdTime=Thu Oct 07 16:10:34 CST 2021, time=2021-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908609, encodeId=2c4a190860901, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Sat Nov 14 22:10:34 CST 2020, time=2020-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1996377, encodeId=afd619963e74f, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Thu Aug 26 00:10:34 CST 2021, time=2021-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787689, encodeId=dfff1e87689cf, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Mon Jun 21 11:10:34 CST 2021, time=2021-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1423406, encodeId=0147142340606, content=<a href='/topic/show?id=075e6130ad' target=_blank style='color:#2F92EE;'>#DNA疫苗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6130, encryptionId=075e6130ad, topicName=DNA疫苗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e4853780813, createdName=mnda, createdTime=Mon Oct 26 01:10:34 CST 2020, time=2020-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1575213, encodeId=dafa15e5213bf, content=<a href='/topic/show?id=6b10112139c' target=_blank style='color:#2F92EE;'>#MACE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11213, encryptionId=6b10112139c, topicName=MACE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2c1f16064818, createdName=lfyang, createdTime=Mon Oct 26 01:10:34 CST 2020, time=2020-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=894209, encodeId=1429894209b8, content=新手新手 需要积分, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=81e45428646, createdName=ms9000001870934422, createdTime=Sat Oct 24 22:52:29 CST 2020, time=2020-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=894169, encodeId=26bd89416932, content=获益非浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIpJVcpECMUATt5iaMc09c4WsFcnLwnayPsFkPE92Gibj9T6rMfhSvaZhnjV8SeXr6Bcl4ddfC4m9Cg/132, createdBy=7d5c2384333, createdName=kulou0314, createdTime=Sat Oct 24 18:48:40 CST 2020, time=2020-10-24, status=1, ipAttribution=)]
    2020-10-26 mnda
  8. [GetPortalCommentsPageByObjectIdResponse(id=2088832, encodeId=b5462088832e8, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10189, encryptionId=53961018913, topicName=I期临床试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45b2276, createdName=839640778, createdTime=Tue Feb 23 16:10:34 CST 2021, time=2021-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1653110, encodeId=c2ec1653110d1, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10187, encryptionId=5b011018e07, topicName=I期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc1f24335670, createdName=医生2402, createdTime=Wed Jun 09 03:10:34 CST 2021, time=2021-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1656034, encodeId=fdb81656034b7, content=<a href='/topic/show?id=2a011829d7' target=_blank style='color:#2F92EE;'>#ACE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1829, encryptionId=2a011829d7, topicName=ACE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=635024767990, createdName=shanyongle, createdTime=Thu Oct 07 16:10:34 CST 2021, time=2021-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908609, encodeId=2c4a190860901, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Sat Nov 14 22:10:34 CST 2020, time=2020-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1996377, encodeId=afd619963e74f, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Thu Aug 26 00:10:34 CST 2021, time=2021-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787689, encodeId=dfff1e87689cf, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Mon Jun 21 11:10:34 CST 2021, time=2021-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1423406, encodeId=0147142340606, content=<a href='/topic/show?id=075e6130ad' target=_blank style='color:#2F92EE;'>#DNA疫苗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6130, encryptionId=075e6130ad, topicName=DNA疫苗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e4853780813, createdName=mnda, createdTime=Mon Oct 26 01:10:34 CST 2020, time=2020-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1575213, encodeId=dafa15e5213bf, content=<a href='/topic/show?id=6b10112139c' target=_blank style='color:#2F92EE;'>#MACE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11213, encryptionId=6b10112139c, topicName=MACE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2c1f16064818, createdName=lfyang, createdTime=Mon Oct 26 01:10:34 CST 2020, time=2020-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=894209, encodeId=1429894209b8, content=新手新手 需要积分, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=81e45428646, createdName=ms9000001870934422, createdTime=Sat Oct 24 22:52:29 CST 2020, time=2020-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=894169, encodeId=26bd89416932, content=获益非浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIpJVcpECMUATt5iaMc09c4WsFcnLwnayPsFkPE92Gibj9T6rMfhSvaZhnjV8SeXr6Bcl4ddfC4m9Cg/132, createdBy=7d5c2384333, createdName=kulou0314, createdTime=Sat Oct 24 18:48:40 CST 2020, time=2020-10-24, status=1, ipAttribution=)]
    2020-10-26 lfyang
  9. [GetPortalCommentsPageByObjectIdResponse(id=2088832, encodeId=b5462088832e8, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10189, encryptionId=53961018913, topicName=I期临床试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45b2276, createdName=839640778, createdTime=Tue Feb 23 16:10:34 CST 2021, time=2021-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1653110, encodeId=c2ec1653110d1, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10187, encryptionId=5b011018e07, topicName=I期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc1f24335670, createdName=医生2402, createdTime=Wed Jun 09 03:10:34 CST 2021, time=2021-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1656034, encodeId=fdb81656034b7, content=<a href='/topic/show?id=2a011829d7' target=_blank style='color:#2F92EE;'>#ACE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1829, encryptionId=2a011829d7, topicName=ACE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=635024767990, createdName=shanyongle, createdTime=Thu Oct 07 16:10:34 CST 2021, time=2021-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908609, encodeId=2c4a190860901, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Sat Nov 14 22:10:34 CST 2020, time=2020-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1996377, encodeId=afd619963e74f, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Thu Aug 26 00:10:34 CST 2021, time=2021-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787689, encodeId=dfff1e87689cf, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Mon Jun 21 11:10:34 CST 2021, time=2021-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1423406, encodeId=0147142340606, content=<a href='/topic/show?id=075e6130ad' target=_blank style='color:#2F92EE;'>#DNA疫苗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6130, encryptionId=075e6130ad, topicName=DNA疫苗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e4853780813, createdName=mnda, createdTime=Mon Oct 26 01:10:34 CST 2020, time=2020-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1575213, encodeId=dafa15e5213bf, content=<a href='/topic/show?id=6b10112139c' target=_blank style='color:#2F92EE;'>#MACE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11213, encryptionId=6b10112139c, topicName=MACE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2c1f16064818, createdName=lfyang, createdTime=Mon Oct 26 01:10:34 CST 2020, time=2020-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=894209, encodeId=1429894209b8, content=新手新手 需要积分, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=81e45428646, createdName=ms9000001870934422, createdTime=Sat Oct 24 22:52:29 CST 2020, time=2020-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=894169, encodeId=26bd89416932, content=获益非浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIpJVcpECMUATt5iaMc09c4WsFcnLwnayPsFkPE92Gibj9T6rMfhSvaZhnjV8SeXr6Bcl4ddfC4m9Cg/132, createdBy=7d5c2384333, createdName=kulou0314, createdTime=Sat Oct 24 18:48:40 CST 2020, time=2020-10-24, status=1, ipAttribution=)]
    2020-10-24 ms9000001870934422

    新手新手 需要积分

    0

  10. [GetPortalCommentsPageByObjectIdResponse(id=2088832, encodeId=b5462088832e8, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10189, encryptionId=53961018913, topicName=I期临床试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45b2276, createdName=839640778, createdTime=Tue Feb 23 16:10:34 CST 2021, time=2021-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1653110, encodeId=c2ec1653110d1, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10187, encryptionId=5b011018e07, topicName=I期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc1f24335670, createdName=医生2402, createdTime=Wed Jun 09 03:10:34 CST 2021, time=2021-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1656034, encodeId=fdb81656034b7, content=<a href='/topic/show?id=2a011829d7' target=_blank style='color:#2F92EE;'>#ACE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1829, encryptionId=2a011829d7, topicName=ACE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=635024767990, createdName=shanyongle, createdTime=Thu Oct 07 16:10:34 CST 2021, time=2021-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908609, encodeId=2c4a190860901, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Sat Nov 14 22:10:34 CST 2020, time=2020-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1996377, encodeId=afd619963e74f, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Thu Aug 26 00:10:34 CST 2021, time=2021-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787689, encodeId=dfff1e87689cf, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Mon Jun 21 11:10:34 CST 2021, time=2021-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1423406, encodeId=0147142340606, content=<a href='/topic/show?id=075e6130ad' target=_blank style='color:#2F92EE;'>#DNA疫苗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6130, encryptionId=075e6130ad, topicName=DNA疫苗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e4853780813, createdName=mnda, createdTime=Mon Oct 26 01:10:34 CST 2020, time=2020-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1575213, encodeId=dafa15e5213bf, content=<a href='/topic/show?id=6b10112139c' target=_blank style='color:#2F92EE;'>#MACE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11213, encryptionId=6b10112139c, topicName=MACE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2c1f16064818, createdName=lfyang, createdTime=Mon Oct 26 01:10:34 CST 2020, time=2020-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=894209, encodeId=1429894209b8, content=新手新手 需要积分, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=81e45428646, createdName=ms9000001870934422, createdTime=Sat Oct 24 22:52:29 CST 2020, time=2020-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=894169, encodeId=26bd89416932, content=获益非浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIpJVcpECMUATt5iaMc09c4WsFcnLwnayPsFkPE92Gibj9T6rMfhSvaZhnjV8SeXr6Bcl4ddfC4m9Cg/132, createdBy=7d5c2384333, createdName=kulou0314, createdTime=Sat Oct 24 18:48:40 CST 2020, time=2020-10-24, status=1, ipAttribution=)]
    2020-10-24 kulou0314

    获益非浅

    0

相关资讯

Clin Cancer Res:新型抗肿瘤DNA疫苗问世,同时靶向7个位点!

目前世界各国研究人员均在进行肿瘤特异性抗原的筛选工作,这令免疫疗法成为众多肿瘤患者的救命药物。但随着各类研究的逐渐深入,研究者发现由于较低的CD8+T细胞免疫原性、载体毒性及有限的特异性靶抗原等因素使得 抗肿瘤疫苗的研发工作进展缓慢。

新冠DNA疫苗INO-4800率先在韩国开始临床试验

国际疫苗研究所(IVI)宣布,流行病防范创新联盟(CEPI)已向INOVIO(NASDAQ:INO)提供690万美元的资助,用于与IVI和韩国国立卫生研究所(KNIH)合作,在韩国开展INOVIO新冠

Mol Med Rep:Der p2‑A20 DNA疫苗能够减弱过敏性炎症

过敏性鼻炎(AR)是一种常见的疾病,需要更加方便,安全和有效的抗原特异性免疫疗法。最近,有研究人员调查了鼻内注射能够共表达der p2和a20蛋白的真核表达载体对过敏性鼻炎小鼠的治疗效果。研究人员通过纳米粒子包装pVAX1-Der p2-A20疫苗,并通过建立了Balb/c过敏性鼻炎小鼠模型。之后评估了DNA疫苗对鼻过敏炎症的治疗效果,并通过ELISA确定了lgE,slgE和lgG以及细胞因子水平

Clin Cancer Res:促进T细胞浸润肿瘤,DNA疫苗联合PD-1治疗HPV相关头颈癌可达到持续完全缓解

近期,来自宾夕法尼亚大学佩尔曼医学院的研究团队发现一种治疗用疫苗可以增强抗体和T细胞,帮助它们浸润到肿瘤中并抵抗人乳头瘤病毒(HPV)相关的头颈癌。该研究团队在两组晚期头颈部鳞状细胞癌(HNSCCa)患者中测试这种免疫治疗方法,发现86%的患者T细胞活性升高。

针对埃博拉病毒的DNA疫苗在临床前研究中显示出长期疗效

发表在《Journal of Infectious Diseases》上的临床前研究数据表明,一种新型合成DNA疫苗可以完全防止埃博拉病毒的感染。

Arthritis Rheumatol:热休克蛋白70 DNA疫苗保护F1小鼠免于罹患系统性红斑狼疮

HSP70 DNA疫苗通过诱导耐受性免疫应答和抗炎免疫反应来抑制鼠类的狼疮,而这些免疫反应与疾病症状减少和小鼠存活期延长相关。

拓展阅读

Biomedicines:2型糖尿病住院患者COVID-19的长期预后

在T2D合并COVID-19患者中,随访观察到住院死亡率、卒中和心血管住院率增加。

Cureus:2型糖尿病状态、糖尿病并发症严重程度指数评分及其与COVID-19严重程度的关系

与非糖尿病患者相比,我们样本中的糖尿病患者发生COVID-19不良临床结果和住院死亡率的几率更高。

Lancet Infect Dis:口服VV116用于治疗轻中度COVID-19成人患者的有效性和安全性评价

目前,治疗COVID-19的医疗需求仍未得到满足,新型抗病毒药物-VV116可用于治疗轻中度COVID-19成人患者,能够显著缩短临床症状持续时间,与其他药物较少发生药物间相互作用,且安全性良好。

论文解读|Yihua Wang教授团队新研究揭示了揭示COVID-19对肺癌治疗和研究的深远影响

该文章揭示了此次大流行对肺癌治疗、临床试验、研究活动的影响。

JAMA Intern Med:COVID-19相关急性肾损伤与长期肾脏结果

与患有其他疾病相关AKI的患者相比,COVID-AKI住院幸存者的MAKE发生率、长期肾功能下降和死亡率均显著较低。

【解读分享】2024 PIDS共识声明:儿童和青少年COVID-19预防和管理指南

本文主要针对儿童和青少年COVID-19预防和管理提供指导建议,涉及COVID-19的危险分层、治疗和预防,点击即可下载查看。